UGT3A2 and metastatic neoplasm: Based on our in silico (Figure 3C) analysis and Wes validation (Figure 4B), we evaluated UGT3A2 protein expression in plasma-derived sEVs from EWS patients (both localized and metastatic disease) and age-matched healthy controls (Supplementary Table S3).